Anticoagulant use in cancer patients

Bibliography

• Sue-Ling HM, Johnston D, McMahon MU, Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986;1:1173-6
   PubMed Web of Science ®Google Scholar
• Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85
   Google Scholar
• Lindblad B, Sternby N, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-11
   PubMed Web of Science ®Google Scholar
• Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002;28:137-40
   PubMed Web of Science ®Google Scholar
• Shen V, Pollak E. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-3
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick S, Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999;78:285-91
   PubMed Web of Science ®Google Scholar
• Sorensen H, Mellemkjaer L, Olsen J, Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50
   PubMed Web of Science ®Google Scholar
• Zacharski LR. Anticoagulants in cancer treatment: malignancy as a solid-phase coagulopathy. Cancer Lett 2002;186:1-9
   PubMed Web of Science ®Google Scholar
• Lee A. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002;28:137-40
   PubMed Web of Science ®Google Scholar
• Gordon SG, Benson B. Analysis of serum cancer procoagulant activity its possible use as a tumor marker. Thromb Res 1989;56:431-40
   PubMed Web of Science ®Google Scholar
• Van Aken BE, Reitsma PH, Rosendaal FR. Interleukin-8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002;116:173-7
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. J Clin Oncol 2010;125(Suppl 2):S120-7
   Google Scholar
• Meyer G, Marjanovic Z, Valcke J, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:1729-35
   PubMed Web of Science ®Google Scholar
• Lee AYY, Levine MN, Baker RI, Low-molecular-weigh heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;34:146-53
   Google Scholar
• Deitcher SR, Kessler CM, Merli G, ; for the ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Haemost 2006;12:389-96
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF. ; LITE Trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009;123:837-44
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:454S-545S
   PubMed Web of Science ®Google Scholar
• Wagman LD, Baird MF, Bennett CL, National Comprehensive Cancer Network. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008;6:716-53
   PubMedGoogle Scholar
• Lyman GH, Khorana AA, Falanga A, American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505
   PubMed Web of Science ®Google Scholar
• Debourdeau P, Kassab Chahmi D, Le Gal G, 2008 SOR* French guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009;20:1459-71
   PubMed Web of Science ®Google Scholar
• Farge D, Kassab-Chahmi D, Bosquet L, 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010;73:31-46
   PubMed Web of Science ®Google Scholar
• Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2009;20(Supp 4):IV182-4
   Google Scholar
• Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006;24:1310-18
   PubMed Web of Science ®Google Scholar
• Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev 2005;19:179-202
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8
   PubMed Web of Science ®Google Scholar
• Lee AYY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4895-901
   PubMed Web of Science ®Google Scholar
• Levine MN, Deitchman D, Julian J, A randomized Phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol 2009;(Suppl): abstr e20514
   Google Scholar
• Hutten BA, Prins MH, Gent M, Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8
   PubMed Web of Science ®Google Scholar
• Kearon C. Long-term management of patients after venous thrombo-embolism. Circulation 2004;110(Suppl I): I-10-18
   Google Scholar
• Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-60
   PubMed Web of Science ®Google Scholar
• Monreal M, Falga C, Valdes M, For the RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2006;4:1950-6
   PubMed Web of Science ®Google Scholar
• Ruiz-Gimenez N, Suarez C, Gonzalez R, ; and the RIETE Investigators. Predictive variables for major bleeding in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:26-31
   PubMed Web of Science ®Google Scholar
• Trujillo-Santos J, Nieto JA, Tiberio G, Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:435-9
   PubMed Web of Science ®Google Scholar
• Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 2002;28:145-9
   PubMed Web of Science ®Google Scholar
• Gladish GW, Chow DH, Maron EM, Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 2006;240:246-55
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, Antithrombotic therapy for venous thromboembolic disease. Chest 2008;133:454S-545S
   PubMedGoogle Scholar
• Khorana AA, Francis CW, Culakova E, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46
   PubMed Web of Science ®Google Scholar
• Agnelli G, Bolis G, Capussotti L, A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS Project. Ann Surg 2006;243:89-95
   PubMed Web of Science ®Google Scholar
• Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma tan squamous cell carcinoma. J Thromb Haemost 2004;2:1760-5
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-9
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink LM, Elice F, Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865-73
   PubMed Web of Science ®Google Scholar
• Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009;27:4858-64
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7
   PubMed Web of Science ®Google Scholar
• Kahn SR, Panju A, Geerts W, Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007;119:145-55
   PubMed Web of Science ®Google Scholar
• Samama MM, Cohen AT, Darmon JY, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Cohen AT, Turpie AG, Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS, Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9
   PubMed Web of Science ®Google Scholar
• Khorana AA, Streiff MB, Farge D, Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919-26
   PubMed Web of Science ®Google Scholar
• Levine M, Hirsh J, Gent M, Double blind randomised trial of very-low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9
   PubMed Web of Science ®Google Scholar
• Haas SK, Kakkar A, Kemkes-Matthes B, Prevention of venous thromboembolism with low molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC studies. J Thromb Haemost 2005;3(Suppl 1):OR059
   Google Scholar
• Perry JR, Rogers L, Laperriere N, PRODIGE: a Phase III randomized placebo controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma (abstract 2011). J Clin Oncol 2007;25:77s
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-9
   PubMed Web of Science ®Google Scholar
• Elice F, Rodeghiero F, Falanga A, Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Hematol 2009;22:115-28
   PubMed Web of Science ®Google Scholar
• Zangari M, Siegel E, Barlogie B, Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-71
   PubMed Web of Science ®Google Scholar
• Desai AA, Vogelzang NJ, Rini BI. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002;95:1629-36
   PubMed Web of Science ®Google Scholar
• Dahut WL, Gulley JL, Arlen PM, Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a metaanalysis. JAMA 2008;300:2277-85
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Anaissie E, Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-21
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-74
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam M, Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766-71
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P, Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl):338S-400S
   Google Scholar
• Bergqvist D, Burmark US, Flordal PA, Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501
   PubMed Web of Science ®Google Scholar
• McLeod RS, Geerts WH, Sniderman KW, Subcutaneous heparin versus low-molecular weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001;233:438-44
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte S, Darmon JY, Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-30
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Agnelli G, Cohen AT, Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer: ENOXACAN II Investigators. N Engl J Med 2002;346:975-80
   PubMed Web of Science ®Google Scholar
• Bottaro FJ, Elizondo MC, Doti C, Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost 2008;99:1104-11
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010;8:1223-9
   PubMed Web of Science ®Google Scholar
• Bern MM, Lokich JJ, Wallach SR, Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomised prospective trial. Ann Intern Med 1990;112:423-8
   PubMed Web of Science ®Google Scholar
• Monreal M, Alastrue A, Rull M, Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-3
   PubMed Web of Science ®Google Scholar
• Mismetti P, Mille D, Laporte S, Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88:67-73
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Bertoglio S, Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-62
   PubMed Web of Science ®Google Scholar
• Couban S, Goodyear M, Burnell M, Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-9
   PubMed Web of Science ®Google Scholar
• Young AM, Billingham LJ, Begun G, Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373:567-74
   PubMed Web of Science ®Google Scholar
• Akl EA, Karmath G, Yosuico V, Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 2007;CD006468
   Google Scholar
• Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcomes in patients with cancer? Cancer Treat Rev 2002;28:151-5
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Khorana AA, Lyman GH, A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110:1149-61
   PubMed Web of Science ®Google Scholar
• Akl EA, van Doormaal FF, Barba M, Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007;CD006652
   Google Scholar
• Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002;32:84-8
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ben Othman T, Kammoun L, Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 2005;92:654-61
   Web of Science ®Google Scholar
• Karthaus M, Kretzschmar A, Kröning H, Dalterparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-96
   PubMed Web of Science ®Google Scholar
• Ruud E, Holmström H, De Lange C, Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies: a randomized, controlled study. Acta Paediatr 2006;95:1053-9
   PubMed Web of Science ®Google Scholar